Article ; Online: European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.
Transplant international : official journal of the European Society for Organ Transplantation
2023 Volume 36, Page(s) 11648
Abstract: Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional ... ...
| Abstract | Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Carcinoma, Hepatocellular/surgery ; Carcinoma, Hepatocellular/pathology ; Liver Neoplasms/surgery ; Liver Neoplasms/pathology ; Liver Transplantation/adverse effects ; Treatment Outcome ; Chemoembolization, Therapeutic/adverse effects ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Immunotherapy | |||||
| Language | English | |||||
| Publishing date | 2023-09-14 | |||||
| Publishing country | Switzerland | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 639435-8 | |||||
| ISSN | 1432-2277 ; 0934-0874 | |||||
| ISSN (online) | 1432-2277 | |||||
| ISSN | 0934-0874 | |||||
| DOI | 10.3389/ti.2023.11648 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2358: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.